Avencell Therapeuticsincis A Clinical Stage Biopharmaceutical Company Dedicated To Developing Advanced Immunotherapies For Challenging Cancerswith A Strong Focus On Car T Cell Therapiesthe Company Was Established Through A Collaboration Involving Blackstone Life Sciencescellex Cell Professionalsand Intellia Therapeuticsand Has Incorporated Gemoab Gmbh To Enhance Its Clinical Programsavencell Has Successfully Raised $250 Million In Initial Funding And An Additional $112 Million In Series B Financing To Support Its Initiatives The Company Utilizes Innovative Technologiescombining Switchable Universal T Cell Technology With Crispr Cas9 Based Platformsthis Approach Allows For Both Patient Specific Andoff The Shelfcell Therapiesaiming To Improve Safety And Efficacyavencell S Product Pipeline Includes Therapies Targeting Acute Myeloid Leukemia And Prostate Cancerwith Ongoing Clinical Trials Demonstrating Promising Resultsthe Company Collaborates With Various Institutions In The Eu To Further Its Research And Development Efforts
